- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04164550
Interpolated Flap Study
August 4, 2020 updated by: University of Pennsylvania
Postoperative Complications, Nasal Function, and Quality of Life Following Interpolated Flap Repair for Post-Mohs Surgical Defects of the Nose: a Multi-center Prospective Observational Cohort Study
The primary purpose of this study is to address the limited knowledge regarding patient well- being and nasal function after interpolated flap repair of post-Mohs surgical defects on the nose.
Improved understanding of the patient experience will allow providers to better counsel their patients pre-operatively and potentially identify patients who may benefit from additional interventions.
Study Overview
Status
Completed
Detailed Description
This project is a multi-center prospective cohort study evaluating postoperative complication rates, quality of life outcomes, and nasal function after interpolated flap repair of post-Mohs surgical defects of the nose.
Our primary outcome is the incidence of short-term complications(within 4 weeks of surgery) defined by the American College of Mohs Surgery as: death, bleeding requiring additional intervention, functional loss attributable to surgery, hospitalization for an operative complication, and surgical site infection.
Secondary outcomes will include incidence of flap necrosis and evaluation of quality of life at 1, 4 and 16 weeks after repair.
Quality of life will be investigated using the Skin Cancer Index (SCI)- a skin cancer specific quality of life instrument and the Nasal Appearance and Functional Evaluation Questionnaire (NAFEQ).
Previous literature has demonstrated that Mohs surgery in the outpatient setting has a very low complication rate but this literature is generally limited to single-institution studies or studies examining smaller repairs.
Furthermore, it has been proven that receiving a skin cancer diagnosis is stressful and patient satisfaction with skin cancer surgery is related to their appearance and scarring or changes in appearance can decrease quality of life.
Our study serves to fill the current literature knowledge gaps by examining repair of large defects and looking at both complications and quality of life outcomes.
Data collection will begin pre-operatively on patients 18 and older who require an interpolated flap repair of a post-Mohs surgical defect.
These patients will then be followed and asked to complete SCI and NAFEQ surveys as well as complication questionnaires at prescribed intervals.
All data will be stored via a secure RedCap database.
Study Type
Observational
Enrollment (Actual)
170
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients age 18 years or greater who are capable of providing informed consent and who may require an interpolated flap repair of their post-Mohs surgical defect will be recruited.
If they consent to the study, they will be asked to complete the SCI and NAFEQ preoperatively.
Patients who subsequently undergo interpolated flap repair will be followed and will complete subsequent SCI and NAFEQ surveys at one week from the date of the interpolated flap inset, 4 weeks after flap takedown, and 16 weeks after flap takedown.
The target enrollment is 180 patients undergoing interpolated flap repair.
Description
Inclusion Criteria:
- Patients 18 years or older who are able to provide informed consent and may require interpolated flap repair of their post-Mohs surgical defect
Exclusion Criteria:
- People who are not adults, not able to give informed consent, or who's wounds are not being repaired by a fellowship trained Mohs surgeon
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complication rate following Mohs micrographic surgery and flap inset
Time Frame: 30 days
|
Short term (30 day) complications are defined by the American College of Mohs Surgery as death, bleeding requiring additional intervention, functional loss attributable to surgery, hospitalization for an operative outcome, and surgical site infection.
|
30 days
|
|
Complication rate following flap takedown
Time Frame: 30 says
|
Short term (30 day) complications are defined by the American College of Mohs Surgery as death, bleeding requiring additional intervention, functional loss attributable to surgery, hospitalization for an operative outcome, and surgical site infection.
|
30 says
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
One week after Mohs- Skin Cancer Index Score
Time Frame: 1 week after Mohs micrographic surgery
|
Skin Cancer Index is 15-item, disease specific, validated, quality of life instrument with three sub-scales, Emotion, Social, Appearance.
A 5-point response format is used for each question where 1 equals "very much" and 5 equals "not at all".
Standardized Scores Range from 0-100 with higher scores indicating higher quality of life.
Standardized scores are obtained by summing the individual scores and dividing them by the number of items in each sub-scale.
|
1 week after Mohs micrographic surgery
|
|
Four weeks after flap takedown- Skin Cancer Index Score
Time Frame: 4 weeks after flap takedown surgery
|
Skin Cancer Index is 15-item, disease specific, validated, quality of life instrument with three sub-scales, Emotion, Social, Appearance.
A 5-point response format is used for each question where 1 equals "very much" and 5 equals "not at all".
Standardized Scores Range from 0-100 with higher scores indicating higher quality of life.
Standardized scores are obtained by summing the individual scores and dividing them by the number of items in each sub-scale.
|
4 weeks after flap takedown surgery
|
|
Sixteen weeks after flap takedown- Skin Cancer Index Score
Time Frame: 16 weeks after flap takedown surgery
|
Skin Cancer Index is 15-item, disease specific, validated, quality of life instrument with three sub-scales, Emotion, Social, Appearance.
A 5-point response format is used for each question where 1 equals "very much" and 5 equals "not at all".
Standardized Scores Range from 0-100 with higher scores indicating higher quality of life.
Standardized scores are obtained by summing the individual scores and dividing them by the number of items in each sub-scale.
|
16 weeks after flap takedown surgery
|
|
One week after Mohs- Nasal Appearance and Functional Evaluation Questionnaire (NAFEQ) Score
Time Frame: 1 week after Mohs micrographic surgery
|
The NAFEQ is a 14-item, validated quality of life instrument with two sections.
The first seven items regard nasal function and airway passage, while the following seven questions assess satisfaction with nasal appearance.
Responses are rated on a 5-point Likert scale where 1 equals "always" or "very dissatisfied", depending on the question, and 5 equals "never" or "very satisfied".
Potential scores range from 7-35 with higher scores indicating greater satisfaction with overall nasal functioning and appearance.
|
1 week after Mohs micrographic surgery
|
|
Four weeks after flap takedown- Nasal Appearance and Functional Evaluation Questionnaire (NAFEQ) Score
Time Frame: 4 weeks after flap takedown surgery
|
The NAFEQ is a 14-item, validated quality of life instrument with two sections.
The first seven items regard nasal function and airway passage, while the following seven questions assess satisfaction with nasal appearance.
Responses are rated on a 5-point Likert scale where 1 equals "always" or "very dissatisfied", depending on the question, and 5 equals "never" or "very satisfied".
Potential scores range from 7-35 with higher scores indicating greater satisfaction with overall nasal functioning and appearance.
|
4 weeks after flap takedown surgery
|
|
Sixteen weeks after flap takedown- Nasal Appearance and Functional Evaluation Questionnaire (NAFEQ) Score
Time Frame: 16 weeks after flap takedown surgery
|
The NAFEQ is a 14-item, validated quality of life instrument with two sections.
The first seven items regard nasal function and airway passage, while the following seven questions assess satisfaction with nasal appearance.
Responses are rated on a 5-point Likert scale where 1 equals "always" or "very dissatisfied", depending on the question, and 5 equals "never" or "very satisfied".
Potential scores range from 7-35 with higher scores indicating greater satisfaction with overall nasal functioning and appearance.
|
16 weeks after flap takedown surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 18, 2018
Primary Completion (ACTUAL)
August 1, 2020
Study Completion (ACTUAL)
August 1, 2020
Study Registration Dates
First Submitted
November 5, 2019
First Submitted That Met QC Criteria
November 12, 2019
First Posted (ACTUAL)
November 15, 2019
Study Record Updates
Last Update Posted (ACTUAL)
August 5, 2020
Last Update Submitted That Met QC Criteria
August 4, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 829285
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Cancer, Non-Melanoma
-
Dartmouth-Hitchcock Medical CenterDartmouth CollegeRecruitingNon-Melanoma Skin Cancer (NMSC) | Benign Skin GrowthUnited States
-
Skin Analytics LimitedInnovate UKCompleted
-
Assiut UniversityNot yet recruitingNon-melanoma Skin Cancer
-
Assistance Publique - Hôpitaux de ParisRecruitingSkin Cancer, Non-MelanomaFrance
-
Xoft, Inc.CompletedNon-melanoma Skin CancerUnited States
-
Technische Universität DresdenCompletedNon-melanoma Skin CancerGermany
-
Assiut UniversityCompleted
-
Skin Analytics LimitedInnovate UKCompleted
-
University of Colorado, DenverWithdrawn